WHO has delayed the emergency use authorization for India's COVID-19 vaccine Covaxin.

WHO has requested more technical details from Bharat Biotech before granting a EUA to Covaxin.

WHO has requested more technical details from Bharat Biotech before granting a EUA to Covaxin.India has administered two homegrown COVID-19 vaccines - Covishield manufactured by the Serum Institute of India and Covaxin by Bharath Biotech to its citizens. Covishield has received an emergency use authorization from the World Health Organization; however, Covaxin is yet to receive it. The EUA for Covaxin is under review, and the vaccine has shown an efficacy rate of 77.8 percent during the phase-3 clinic trials.

According to an NDTV report dated September 27, the emergency use approval for Covaxin was further delayed, as WHO sought some technical answers from its manufacturer. News18 quoted a WHO official as saying that the process might take a few weeks.

According to Bharath Biotech, the company submitted all the documents required for approval on July 9. 2021. It expects Covaxin to receive EUL from WHO as soon as possible, chairman and managing director of Bharat Biotech Dr. Krishna Ella said.

Without EUA, the vaccine won't get recognized and accepted in most countries, and the delay is likely to affect students and those planning to travel internationally.

Therefore, it's true that WHO has delayed the emergency use authorization for India's COVID-19 vaccine Covaxin.

The COVID-19 pandemic has given rise to a lot of potentially dangerous misinformation. For reliable advice on COVID-19, including symptoms, prevention, and available treatment, please refer to the World Health Organization or your national healthcare authority.